公开(公告)号：US11110090B2

公开(公告)日：2021-09-07

申请号：US16914518

申请日：2020-06-29

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Jianyong Chen

IPC: A61K31/506 ,  C07D405/14 ,  C07D401/12 ,  A61P35/00

Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.

公开(公告)号：US11718613B2

公开(公告)日：2023-08-08

申请号：US17023426

申请日：2020-09-17

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Jianyong Chen

IPC: C07D471/04 ,  A61P35/02 ,  A61P35/00

CPC classification number: C07D471/04 ,  A61P35/00 ,  A61P35/02

Abstract: The present disclosure provides compounds having Formula I-A:




and the pharmaceutically acceptable salts and solvates thereof, wherein A, X1, X2, X3 R1a, R1b, E, and are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a disease, disorder, or condition responsive to Bcl-2 protein inhibition such as cancer.

公开(公告)号：US11498928B2

公开(公告)日：2022-11-15

申请号：US17049100

申请日：2020-01-17

Applicant: ASCENTAGE PHARMA (SUZHOU) CO., LTD. ,  THE REGENTS OF THE UNIVERSITY OF MICHIGAN ,  ASCENTAGE PHARMA GROUP CORP LIMITED

Inventor： Jianyong Chen ,  Yunlong Zhou ,  Guozhi Tang ,  Chengzhe Wu ,  Leilei Zhao ,  Lingling Jiao ,  Binghua Sheng ,  Shaomeng Wang ,  Chao-Yie Yang ,  Hao Chen ,  Wenliang Hu ,  Yu Jing

IPC: C07D513/20 ,  C07D515/20 ,  C07D498/08 ,  A61K31/553 ,  A61P35/00 ,  C07D513/10 ,  C07D519/00

Abstract: Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R9a, R9b, R9c, R9d, X, Y, Z, Z1, W, and (aa) are as defined as set forth in the specification. Provided are also compounds of Formula (I-A) for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.

公开(公告)号：US20200330464A1

公开(公告)日：2020-10-22

申请号：US16914518

申请日：2020-06-29

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Jianyong Chen

IPC: A61K31/506 ,  C07D405/14 ,  C07D401/12 ,  A61P35/00

Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.

公开(公告)号：US10781208B2

公开(公告)日：2020-09-22

申请号：US16347630

申请日：2017-11-17

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Jianyong Chen ,  Liu Liu ,  Xuyuan Dong ,  Chao-Yie Yang ,  Donna McEachern ,  Shaomeng Wang

IPC: C07D471/04 ,  A61P35/00

Abstract: The present disclosure provides compounds represented by Formula (I), and the pharmaceutically acceptable salts and solvates thereof wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7, E and (B) are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer. and ®

公开(公告)号：US20190315739A1

公开(公告)日：2019-10-17

申请号：US16317056

申请日：2017-08-04

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Jianyong Chen

IPC: C07D471/04 ,  A61P35/02

Abstract: The present disclosure provides compounds having Formula I-A: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X1, X2, X3 R1a, R1b E, and = are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a disease, disorder, or condition responsive to Bcl-2 protein inhibition such as cancer.

公开(公告)号：US20210002277A1

公开(公告)日：2021-01-07

申请号：US17023426

申请日：2020-09-17

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Jianyong Chen

IPC: C07D471/04 ,  A61P35/02 ,  A61P35/00

Abstract: The present disclosure provides compounds having Formula I-A: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X1, X2, X3 R1a, R1b, E, and are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a disease, disorder, or condition responsive to Bcl-2 protein inhibition such as cancer

公开(公告)号：US20190315741A1

公开(公告)日：2019-10-17

申请号：US16347630

申请日：2017-11-17

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Jianyong Chen ,  Liu Liu ,  Xuyuan Dong ,  Chao-Yie Yang ,  Donna McEachern ,  Shaomeng Wang

IPC: C07D471/04 ,  A61P35/00

Abstract: The present disclosure provides compounds represented by Formula (I), and the pharmaceutically acceptable salts and solvates thereof wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7, E and (B) are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer. and (R)

公开(公告)号：US20180354950A1

公开(公告)日：2018-12-13

申请号：US16051816

申请日：2018-08-01

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Jianyong Chen

IPC: C07D471/04 ,  A61P35/00

CPC classification number: C07D471/04 ,  A61P35/00

Abstract: The present disclosure provides compounds having Formula I-A: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X1, X2, X3 R1a, R1b, E, and are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a disease, disorder, or condition responsive to Bcl-2 protein inhibition such as cancer.

公开(公告)号：US20210340158A1

公开(公告)日：2021-11-04

申请号：US17049100

申请日：2020-01-17

Applicant: ASCENTAGE PHARMA (SUZHOU) CO., LTD. ,  THE REGENTS OF THE UNIVERSITY OF MICHIGAN ,  ASCENTAGE PHARMA GROUP CORP LIMITED

Inventor： Jianyong Chen ,  Yunlong Zhou ,  Guozhi Tang ,  Chengzhe Wu ,  Leilei Zhao ,  Lingling Jiao ,  Binghua Sheng ,  Shaomeng Wang ,  Chao-Yie Yang ,  Hao Chen ,  Wenliang Hu ,  Yu Jing

IPC: C07D513/20 ,  C07D513/10 ,  C07D519/00 ,  A61P35/00

Abstract: Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R9a, R9b, R9c, R9d, X, Y, Z, Z1, W, and (aa) are as defined as set forth in the specification. Provided are also compounds of Formula (I-A) for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.